The Food and Drug Administration (FDA) has approved Uplizna ® (inebilizumab-cdon) for the treatment of immunoglobulin G4-related disease (IgG4-RD) in adult patients.

The Company expects to have topline data from 2 trials assessing the effect of reproxalap on dry eye disease symptoms available in the second quarter of 2025.

Receipt of zoster vaccine reduces probability of new dementia diagnosis over seven-year period by 3.5 percentage points.

New treatments for Prader-Willi Syndrome and hemophilia; FDA fast tracks a chlamydia vaccine candidate; over-the-counter test cleared for identifying chlamydia, gonorrhea and trichomoniasis.

Program increases receipt of follow-up colonoscopy among persons aged 50 to 75 years with an abnormal stool test result.

"If artificial intelligence is going to be impactful, it needs to be better than the human eye," said the lead researcher.

The Food and Drug Administration (FDA) has cleared the Visby Medical Women’s Sexual Health Test for use at home to test for ...

HealthDay News — Use of hormonal contraceptives postpartum is associated with an increased risk for developing postpartum depression, according to a study published online March 31 in JAMA Network ...

The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ® (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid ...

BeiGene has made the decision to end the clinical development program for ociperlimab (BGB-A1217) for the treatment of non-small cell lung cancer ...

The FDA is expected to decide on treatments for COPD, psoriasis, rare neuroendocrine tumors, and a next-generation COVID-19 vaccine.

Detailed study results will be presented at an upcoming medical meeting and submitted to health authorities later this year to expand Palynziq’s label to include adolescents.